Building effective institutional frameworks to support pharmacogenetic research: an international empirical analysis
by Sibylle Gaisser, Marieke Dreiling, Juliane Hartig, Michael M. Hopkins, Jim Ryan, Dolores Ibarreta
International Journal of Biotechnology (IJBT), Vol. 10, No. 6, 2008

Abstract: As science unravels the genetic basis of disease, the opportunities offered by pharmacogenetics and pharmacogenomics (PGx) for future healthcare become more and more apparent. The objective of this paper is to analyse the current state of PGx research and explore future strategies for more efficient research projects and supportive infrastructures. Based on internet searches and an online survey of public research groups, the current focus of PGx technology and the institutional framework conditions for its performance were determined. The main areas of PGx research are the liver, neoplasms and the cardiovascular and central nervous systems. Collaborations are important for knowledge transfer between the private and public sectors. However, for strategic and confidentiality reasons, most collaborations are restricted to preclinical development, early stage clinical studies and the development of methods.

Online publication date: Fri, 09-Jan-2009

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Biotechnology (IJBT):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email